```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  NOV 21   CAS patent coverage to include exemplified prophetic
                   substances identified in English-, French-, German-,
                   and Japanese-language basic patents from 2004-present
 NEWS  3  NOV 26   MARPAT enhanced with FSORT command
 NEWS  4  NOV 26   MEDLINE year-end processing temporarily halts
                   availability of new fully-indexed citations
 NEWS  5  NOV 26   CHEMSAFE now available on STN Easy
 NEWS  6  NOV 26   Two new SET commands increase convenience of STN
                   searching
 NEWS  7  DEC 01   ChemPort single article sales feature unavailable
 NEWS  8  DEC 12   GBFULL now offers single source for full-text
                   coverage of complete UK patent families
 NEWS  9  DEC 17   Fifty-one pharmaceutical ingredients added to PS
 NEWS 10  JAN 06   The retention policy for unread STNmail messages
                   will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 11  JAN 07   WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                   Classification Data

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:21:55 ON 20 JAN 2009

=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 11:22:17 ON 20 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2009 HIGHEST RN 1094210-83-9
DICTIONARY FILE UPDATES: 19 JAN 2009 HIGHEST RN 1094210-83-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10549546\10549546p.str



chain nodes :
7 8 9 10 11 12 13 14 18
ring nodes :
1 2 3 4 5 6
chain bonds :
6-7 7-8 8-9 8-18 9-10 10-11 11-12 12-13 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 8-18 12-13 12-14
exact bonds :
6-7 8-9 9-10 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 18:CLASS
Element Count :
Node 14: Limited
N,N2
C,C4

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 11:23:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    15098 TO ITERATE

 13.2% PROCESSED     2000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       294599 TO   309321
PROJECTED ANSWERS:              1 TO      314

L2            1 SEA SSS SAM L1

=> d scan

L2   1 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   1H-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-
     methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-,
     (2E)-2-butenedioate (1:1) (9CI)
MF   C26 H42 N4 O5 S . C4 H4 O4

     CM   1
```




```
     CM   2

Double bond geometry as shown.
```




```
ALL ANSWERS HAVE BEEN SCANNED


=> s l1 full
FULL SEARCH INITIATED 11:23:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   306603 TO ITERATE
```

100.0% PROCESSED 306603 ITERATIONS 387 ANSWERS
SEARCH TIME: 00.00.08

L3 387 SEA SSS FUL L1

=> d scan

L3 387 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, N-[2-[2-[4-hydroxy-4-(3-pyridinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, hydrochloride (1:1)
MF C24 H33 N3 O6 S . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 387 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-morpholinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI)
MF C26 H43 N3 O6 S . C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.

L3 387 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]ethoxy]ethyl]-
MF C25 H41 N3 O5 S
CI COM





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	186.84	187.06

FILE 'CAPLUS' ENTERED AT 11:24:05 ON 20 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Jan 2009 VOL 150 ISS 4
FILE LAST UPDATED: 19 Jan 2009 (20090119/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l3
L4          19 L3

=> s l3 and (pd<=20030325 or ad<=20030325 or prd<=20030325)
            19 L3
      23758155 PD<=20030325
                 (PD<=20030325)
       4564277 AD<=20030325
                 (AD<=20030325)
       4033107 PRD<=20030325
                 (PRD<=20030325)
L5           9 L3 AND (PD<=20030325 OR AD<=20030325 OR PRD<=20030325)

=> d l5 ibib hitstr 1-9

L5   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2004:857596  CAPLUS
DOCUMENT NUMBER:          141:350198
TITLE:                    Heterocyclic (piperazine- and piperidine-containing)
                          benzenesulfonamide derivatives, method for their
                          production, therapeutic compositions, and use thereof
                          for treatment of pain and inflammation
INVENTOR(S):              Barth, Martine; Bondoux, Michel; Dodey, Pierre;
                          Massardier, Christine; Thomas, Didier; Luccarini,
                          Jean-Michel
PATENT ASSIGNEE(S):       Laboratoires Fournier S.A., Fr.
SOURCE:                   PCT Int. Appl., 127 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     -----------------    ----   --------    --------------------   --------
     WO 2004087700         A1    20041014    WO 2004-FR723          20040324 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
```

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

FR 2852958	A1	20041001	FR 2003-3602	20030325	<--
FR 2852958	B1	20050624			
FR 2853648	A1	20041015	FR 2003-4530	20030411	
FR 2853648	B1	20060818			
AU 2004226197	A1	20041014	AU 2004-226197	20040324	<--
CA 2519110	A1	20041014	CA 2004-2519110	20040324	<--
EP 1606288	A1	20051221	EP 2004-742333	20040324	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
BR 2004008689	A	20060328	BR 2004-8689	20040324	<--
JP 2006521333	T	20060921	JP 2006-505749	20040324	<--
IN 2005DN03814	A	20070817	IN 2005-DN3814	20050826	<--
US 20060178360	A1	20060810	US 2005-549546	20050914	
NO 2005004361	A	20051101	NO 2005-4361	20050920	<--
PRIORITY APPLN. INFO.:			FR 2003-3602	A 20030325	<--
			FR 2003-4530	A 20030411	
			WO 2004-FR723	A 20040324	

OTHER SOURCE(S): MARPAT 141:350198

IT 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(drug candidate, resolution; preparation of piperazine- and piperidine-containing
benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-09-2 CAPLUS

CN Benzenesulfonamide, N-[2-[2-[4-(1-azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



IT 766558-14-9P, N-[2-[2-[4-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-14-9 CAPLUS

CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-13-8
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 766558-11-6P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide 766558-25-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775286-20-9P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide 775286-41-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-57-5P, N-[2-[2-(4-Amino-1-piperidinyl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide 775287-58-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-11-6 CAPLUS

CN Benzenesulfonamide, N-[2-[2-[4-(3S)-1-azabicyclo[2.2.2]oct-3-yl-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 766558-25-2 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775286-20-9 CAPLUS
CN Benzenesulfonamide, 2,6-dichloro-4-fluoro-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775286-41-4 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775287-57-5 CAPLUS
CN Benzenesulfonamide, N-[2-[2-(4-amino-1-piperidinyl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 775287-58-6 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



IT 766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]piperazine bis(trifluoroacetate) 766558-08-1P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N,2,4,6-tetramethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]piperazine bis(trifluoroacetate) 766558-18-3P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]piperazine bis(trifluoroacetate) 766558-20-7P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]piperazine bis(trifluoroacetate) 766558-22-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]piperazine bis(trifluoroacetate) 766558-24-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(dimethylamino)propyl]piperazine bis(trifluoroacetate) 766558-26-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 766558-28-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 766558-30-9P, 1-(1-Azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1H-1,4-diazepine fumarate 775285-46-6P, N-[2-[2-[4-[3-(1-Azetidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-48-8P, N-[2-[2-[4-(1-Methyl-3-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-54-6P, N-[2-[2-[4-[(1-Methyl-2-imidazolyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-56-8P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide

difumarate 775285-58-0P,
N-[2-[2-[4-[3-(Dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-60-4P, N-[2-[2-[4-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-62-6P, N-[2-[2-[4-[3-(1-Pyrrolidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-66-0P, N-[2-[2-[4-(8-Cyclopropyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-68-2P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-72-8P, N-[2-[2-[4-(1-Cyclopropyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-74-0P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-76-2P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-78-4P, N-[2-[2-[4-[1-(1,1-Dimethylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-80-8P, N-[2-[2-[4-[(1-Methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-82-0P, N-[2-[2-[4-[3-(Dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide difumarate 775285-84-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide difumarate 775285-85-3P, N-[2-[2-[4-[2-(1-Methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-87-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)hexahydro-1H-1,4-diazepin-1-yl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-89-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-91-1P, N-[2-[2-[4-[1-(1-Methylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-93-3P, N-[2-[2-[4-[3-(1-Piperidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-95-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methoxy-N-methylbenzenesulfonamide difumarate 775285-97-7P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide fumarate 775285-99-9P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dichlorobenzenesulfonamide fumarate 775286-01-6P, N-[2-[2-[4-(1,2,2,6,6-Pentamethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis(trifluoroacetate) 775286-03-8P, N-[2-[2-[4-[3-(4-Methyl-1-piperazinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-05-0P, N-[2-[2-[4-(8-Ethyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-07-2P, N-[2-[2-[4-[3-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-09-4P,

N-[2-[2-[4-[8-(1-Methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-11-8P, N-[2-[2-[4-[3-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)-3-oxopropyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis(trifluoroacetate) 775286-13-0P, N-[2-[2-[4-[2-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifumarate 775286-17-4P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775286-19-6P, N-[2-[2-[4-[2-(Diethylamino)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775286-21-0P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide difumarate 775286-22-1P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide 775286-23-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide difumarate 775286-24-3P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide 775286-25-4P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide difumarate 775286-26-5P , N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide 775286-27-6P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide difumarate 775286-28-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-2,3,6-trimethyl-N-methylbenzenesulfonamide 775286-29-8P, 4-Methoxy-N,2,3,6-tetramethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-30-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-31-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-methyl-4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-32-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-methyl-4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide difumarate 775286-34-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775286-35-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-amino-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-36-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-amino-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide fumarate 775286-38-9P, N-[2-[2-[4-[2-(Dimethylamino)-1,1-dimethylethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775286-40-3P, N-[2-[2-[4-[2-(Dimethylamino)-1-hydroxyethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775286-42-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-44-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-48-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-50-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[4-(1-methylethyl)-1-piperazinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-52-7P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-

piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-56-1P, N-[2-[2-[4-[2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-58-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-[methyl(1-methylethyl)amino]ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-60-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(1-methyl-4-piperidinyl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-62-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1-(1-methylethyl)-4-piperidinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-64-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-ethyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-66-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-cyclopropyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-68-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-70-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-azetidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-72-1P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-74-3P, N-[2-[2-[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775286-78-7P, 2,4-Dichloro-N,3-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-80-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(1-azetidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-82-3P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-[2-(dimethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-84-5P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-86-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(1-pyrrolidinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-88-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(4-ethyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-92-5P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-94-7P, N-Methyl-4-methoxy-2,6-dichloro-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-96-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate 775286-98-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-00-8P, N-[2-[2-[4-[2-(Ethylmethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775287-02-0P, N-[2-[2-[4-[2-(Diethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775287-04-2P, 4-Methoxy-N-(1-methylethyl)-2,6-dimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-06-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-08-6P, N-[2-[2-[4-[(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775287-10-0P, 4-Methoxy-N-[2-[2-[4-[2-(1-methyl-4-piperidinyl)ethyl]-1-piperidinyl]-2-

oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate
775287-12-2P, 4-Methoxy-N-[2-[2-[4-[2-(1-piperidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate
775287-14-4P, 4-Methoxy-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N-methyl-2-(trifluoromethyl)benzenesulfonamide trifluoroacetate 775287-16-6P, 4-Methoxy-N-[2-[2-[4-[2-(1-methyl-4-piperazinyl)-2-oxoethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate
775287-18-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(dimethylamino)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-20-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(1-azetidinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-22-4P, N,2,4,6-Tetramethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate 775287-24-6P, N-Methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]-2-(trifluoromethyl)benzenesulfonamide trifluoroacetate
775287-26-8P, 4-Methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]-2-(trifluoromethyl)benzenesulfonamide trifluoroacetate 775287-28-0P, N,2,4,6-Tetramethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate 775287-30-4P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate
775287-32-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(dimethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-34-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-cyclopropyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-36-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[4-(1,1-dimethylethyl)-1-piperazinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate
775287-38-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-40-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-methyl-1-piperazinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate
775287-41-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-morpholinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
775287-42-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-morpholinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-43-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-44-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate
775287-45-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-46-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-47-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-48-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate
775287-49-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-azetidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
775287-50-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-azetidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-51-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
775287-52-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-

(dimethylamino)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-54-2P, N-[2-[2-(4,4'-Bipiperidin-1-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775287-55-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-56-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-59-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-60-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(methylamino)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-61-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-62-2P

, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-63-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide 775287-64-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide fumarate 775287-66-6P

, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[1-oxo-2-(4-methyl-1-piperazinyl)ethyl]-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-67-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide dihydrochloride 775287-68-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775288-89-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(diethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-06-9 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-05-8
CMF C24 H40 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-08-1 CAPLUS

CN Benzenesulfonamide, N-[2-[2-[4-(1-azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N,2,4,6-tetramethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-07-0
CMF C25 H40 N4 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-10-5 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-09-2
CMF C25 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-12-7 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-11-6
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-16-1 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-15-0
CMF C25 H42 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-18-3 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-,

2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-17-2
CMF C24 H40 N4 O6 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-20-7 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[2-(1-piperidinyl)ethyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-19-4
CMF C25 H42 N4 O5 S

PAGE 1-A



OMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-22-9 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-21-8
CMF C26 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-24-1 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-23-0

CMF C23 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-26-3 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX

NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-30-9 CAPLUS
CN 1H-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-29-6
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-46-6 CAPLUS
CN Piperazine, 1-[3-(1-azetidinyl)propyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate

(1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-45-5
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-48-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-3-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-47-7
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-54-6 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-

dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(1-methyl-1H-imidazol-2-yl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-53-5
CMF C23 H35 N5 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-56-8 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-55-7
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-58-0 CAPLUS

CN 1-Piperazinepropanamine, 4-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-57-9
CMF C24 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-60-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-59-1
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-62-6 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-61-5
CMF C26 H44 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775285-66-0 CAPLUS
CN Piperazine, 1-(8-cyclopropyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-65-9
CMF C28 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-68-2 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-67-1
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-72-8 CAPLUS
CN Piperazine, 1-(1-cyclopropyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-71-7
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-74-0 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-73-9
CMF C28 H46 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-76-2 CAPLUS
CN Piperazine, 1-(1-ethyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-75-1
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-78-4 CAPLUS
CN Piperazine, 1-[1-(1,1-dimethylethyl)-4-piperidinyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-77-3
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-80-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(1-methyl-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-79-5
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-82-0 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-81-9
CMF C21 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-84-2 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-83-1
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-85-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(1-methyl-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-79-5
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-87-5 CAPLUS
CN 1H-1,4-Diazepine, hexahydro-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-86-4
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-89-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-88-6
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-91-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-90-0
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-93-3 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-92-2
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-95-5 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-94-4
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-97-7 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-ethyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-96-6
CMF C23 H36 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-99-9 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-98-8
CMF C23 H34 Cl2 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-01-6 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1,2,2,6,6-pentamethyl-4-piperidinyl)-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 775286-00-5
CMF C28 H48 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-03-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-02-7
CMF C26 H45 N5 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-05-0 CAPLUS
CN Piperazine, 1-(8-ethyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-04-9
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-07-2 CAPLUS
CN Piperazine, 1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-06-1
CMF C27 H47 N5 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-09-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[8-(1-methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-08-3
CMF C28 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-11-8 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-oxopropyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 775286-10-7
CMF C27 H45 N5 O6 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-13-0 CAPLUS
CN Piperazine, 1-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-12-9
CMF C26 H45 N5 O5 S

PAGE 1-A





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-17-4 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-16-3
CMF C26 H42 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-19-6 CAPLUS
CN 1-Piperazineethanamine, N,N-diethyl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate

(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-18-5
CMF C24 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-21-0 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-20-9
CMF C21 H31 Cl2 F N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-22-1 CAPLUS
CN Benzenesulfonamide, 4-bromo-2,6-dichloro-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775286-23-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-22-1
CMF C21 H31 Br Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-24-3 CAPLUS
CN Benzenesulfonamide, 2,4,6-trichloro-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775286-25-4 CAPLUS
CN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-24-3

CMF C21 H31 Cl3 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-26-5 CAPLUS
CN Benzenesulfonamide, 2,4-dichloro-N,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775286-27-6 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-26-5
CMF C22 H34 Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-28-7 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,3,6-tetramethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775286-29-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-28-7
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775286-30-1 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]- (CA INDEX NAME)



RN 775286-31-2 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-methyl-4-piperidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

OMe

RN 775286-32-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-methyl-4-piperidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-31-2
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-34-5 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 775286-33-4
CMF C23 H38 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-35-6 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-(6-amino-3-pyridinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 775286-36-7 CAPLUS
CN Piperazine, 1-(6-amino-3-pyridinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-35-6
CMF C23 H33 N5 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-38-9 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[2-(dimethylamino)-1,1-dimethylethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775286-37-8
CMF C25 H43 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-40-3 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[2-(dimethylamino)-1-hydroxyethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775286-39-0
CMF C23 H39 N3 O6 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-42-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-41-4
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-44-7 CAPLUS

CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-43-6
CMF C25 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-48-1 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-47-0
CMF C25 H41 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775286-50-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-49-2
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-52-7 CAPLUS
CN Piperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-51-6
CMF C26 H43 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-56-1 CAPLUS
CN Piperidine, 4-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-55-0
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-58-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(1-methylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-57-2
CMF C25 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775286-60-7 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-59-4
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-62-9 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-(1-methylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-61-8
CMF C27 H45 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-64-1 CAPLUS
CN 4,4'-Bipiperidine, 1-ethyl-1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-63-0
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-66-3 CAPLUS
CN 4,4'-Bipiperidine, 1-cyclopropyl-1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-65-2
CMF C27 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-68-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-67-4
CMF C25 H41 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-70-9 CAPLUS
CN Piperidine, 4-[2-(1-azetidinyl)-1,1-dimethylethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-69-6
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-72-1 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-71-0
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775286-74-3 CAPLUS
CN Piperidine, 4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-73-2
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775286-78-7 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(2,4-dichloro-3-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-77-6
CMF C23 H35 Cl2 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-80-1 CAPLUS
CN Piperidine, 4-[2-(1-azetidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-79-8
CMF C24 H39 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775286-82-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-81-2
CMF C21 H33 Cl2 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-84-5 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-83-4
CMF C23 H35 Cl2 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-86-7 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-pyrrolidinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-85-6
CMF C24 H39 N3 O5 S





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-88-9 CAPLUS
CN Piperidine, 4-[(4-ethyl-1-piperazinyl)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-87-8
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-92-5 CAPLUS
CN Piperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-91-4
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-94-7 CAPLUS
CN Piperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-93-6
CMF C23 H36 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-96-9 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775286-95-8
CMF C28 H47 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-98-1 CAPLUS
CN Piperidine, 4-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-97-0
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-00-8 CAPLUS
CN 4-Piperidineethanamine, N-ethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-99-2
CMF C24 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-02-0 CAPLUS
CN 4-Piperidineethanamine, N,N-diethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-01-9
CMF C25 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-04-2 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-

methylethyl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-03-1
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775287-06-4 CAPLUS
CN Piperidine, 4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-05-3
CMF C27 H45 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-08-6 CAPLUS
CN Piperidine, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-07-5
CMF C26 H44 N4 O5 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-10-0 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-methyl-4-piperidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-09-7
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-12-2 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-11-1
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-14-4 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N-methyl-N-[2-[2-oxo-2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]ethoxy]ethyl]-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775287-13-3
CMF C24 H36 F3 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-16-6 CAPLUS
CN Piperazine, 1-[[1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]acetyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-15-5
CMF C26 H42 N4 O6 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-18-8 CAPLUS
CN 4-Piperidinemethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-17-7
CMF C22 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-20-2 CAPLUS
CN Piperidine, 4-(1-azetidinylmethyl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-19-9
CMF C23 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-22-4 CAPLUS
CN Benzenesulfonamide, N,2,4,6-tetramethyl-N-[2-[2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775287-21-3
CMF C25 H41 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-24-6 CAPLUS
CN Benzenesulfonamide, N-methyl-N-[2-[2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethoxy]ethyl]-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775287-23-5
CMF C23 H34 F3 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-26-8 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N-methyl-N-[2-[2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethoxy]ethyl]-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775287-25-7
CMF C24 H36 F3 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-28-0 CAPLUS
CN Benzenesulfonamide, N,2,4,6-tetramethyl-N-[2-[2-oxo-2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775287-27-9
CMF C25 H41 N3 O4 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-30-4 CAPLUS
CN Piperidine, 1-[[2-[[(2,6-dichloro-4-

methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-29-1
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-32-6 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-31-5
CMF C23 H39 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-34-8 CAPLUS
CN Piperidine, 4-(4-cyclopropyl-1-piperazinyl)-1-[[2-[[(4-methoxy-2,6-

dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-33-7
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-36-0 CAPLUS
CN Piperidine, 4-[4-(1,1-dimethylethyl)-1-piperazinyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-35-9
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-38-2 CAPLUS

CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-37-1
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-40-6 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-methyl-1-piperazinyl)ethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-39-3
CMF C26 H44 N4 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-41-7 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-morpholinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775287-42-8 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-morpholinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-41-7
CMF C26 H43 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 775287-43-9 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperidinyl]ethoxy]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 775287-44-0 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-43-9
CMF C26 H43 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-45-1 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775287-46-2 CAPLUS
CN Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-45-1
CMF C28 H48 N4 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-47-3 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 775287-48-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-47-3
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-49-5 CAPLUS

CN Benzenesulfonamide, N-[2-[2-[4-[3-(1-azetidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 775287-50-8 CAPLUS
CN Piperidine, 4-[3-(1-azetidinyl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-49-5
CMF C25 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-51-9 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 775287-52-0 CAPLUS
CN 4-Piperidinepropanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-51-9
CMF C24 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-54-2 CAPLUS
CN Benzenesulfonamide, N-[2-(2-[4,4'-bipiperidin]-1-yl-2-oxoethoxy)ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775287-53-1
CMF C24 H39 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-55-3 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775287-56-4 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-55-3
CMF C22 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-59-7 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 775287-58-6
CMF C27 H44 N4 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2

RN 775287-60-0 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(methylamino)-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775287-61-1 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775287-62-2 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 775287-61-1
CMF C28 H46 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-63-3 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethoxy]ethyl]- (CA INDEX NAME)



RN 775287-64-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-piperazinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-63-3
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-66-6 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-methyl-1-piperazinyl)acetyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 775287-65-5
CMF C26 H42 N4 O6 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-67-7 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 775287-68-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775288-89-6 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[2-(diethylamino)-1,1-dimethylethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 775288-88-5
CMF C27 H47 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 775288-66-9P, 4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 775288-67-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-(1-piperazinyl)ethoxy]ethyl]benzenesulfonamide 775288-69-2P, 4-[3-[4-[[2-[[(4-Methoxy-2,6-

dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]propyl]-1-piperidinecarboxylic acid phenylmethyl ester 775288-70-5P, 4-[4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 775288-73-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-nitro-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775288-74-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(3-hydroxypropyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775288-75-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-[[(4-methylphenyl)sulfonyl]oxy]propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775288-76-1P, 1'-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4,4'-bipiperidine-1-carboxylic acid 1,1-dimethylethyl ester 775288-77-2P, [2-[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]ethyl](methyl)carbamic acid 1,1-dimethylethyl ester 775288-78-3P, [1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]carbamic acid 1,1-dimethylethyl ester 775288-79-4P, [1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl](methyl)carbamic acid 1,1-dimethylethyl ester 775288-82-9P, 4-[[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl]-1-piperazinecarboxylic acid phenylmethyl ester 775288-83-0P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinecarboxylic acid ethyl ester 775288-84-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinecarboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 775288-66-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 775288-67-0 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-(1-piperazinyl)ethoxy]ethyl]- (CA INDEX NAME)



RN 775288-69-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[4-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]propyl]-, phenylmethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-70-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 775288-73-8 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(6-nitro-3-pyridinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)



RN 775288-74-9 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-(3-hydroxypropyl)-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



RN 775288-75-0 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-[[(4-methylphenyl)sulfonyl]oxy]propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-76-1 CAPLUS
CN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 775288-77-2 CAPLUS
CN Carbamic acid, [2-[1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OBu-t

RN 775288-78-3 CAPLUS
CN Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-79-4 CAPLUS
CN Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-82-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl]-, phenylmethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-83-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, ethyl ester (CA INDEX NAME)



RN 775288-84-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:800854 CAPLUS
DOCUMENT NUMBER: 141:314016
TITLE: Preparation of benzenesulfonamides as Bradykinin B1 receptors antagonists for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean Michel

PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: Fr. Demande, 27 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2852958	A1	20041001	FR 2003-3602	20030325 <--
FR 2852958	B1	20050624		
AU 2004226197	A1	20041014	AU 2004-226197	20040324 <--
CA 2519110	A1	20041014	CA 2004-2519110	20040324 <--
WO 2004087700	A1	20041014	WO 2004-FR723	20040324 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1606288	A1	20051221	EP 2004-742333	20040324 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008689	A	20060328	BR 2004-8689	20040324 <--
CN 1764661	A	20060426	CN 2004-80007762	20040324 <--
JP 2006521333	T	20060921	JP 2006-505749	20040324 <--
IN 2005DN03814	A	20070817	IN 2005-DN3814	20050826 <--
NO 2005004361	A	20051101	NO 2005-4361	20050920 <--

PRIORITY APPLN. INFO.:
FR 2003-3602 A 20030325 <--
FR 2003-4530 A 20030411
WO 2004-FR723 A 20040324

OTHER SOURCE(S): MARPAT 141:314016

IT 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-09-2 CAPLUS

CN Benzenesulfonamide, N-[2-[2-[4-(1-azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)



IT 766558-11-6P, N-[2-[2-[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)
RN 766558-11-6 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-(3S)-1-azabicyclo[2.2.2]oct-3-yl-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]piperazine bistrifluoroacetate 766558-08-1P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N-methyl-2,4,6-trimethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-14-9P, N-[2-[2-[4-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]piperazine bistrifluoroacetate 766558-18-3P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]piperazine bistrifluoroacetate 766558-20-7P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]piperazine bistrifluoroacetate 766558-22-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]piperazine bistrifluoroacetate 766558-24-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(dimethylamino)propyl]piperazine bistrifluoroacetate 766558-26-3P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bistrifluoroacetate 766558-28-5P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 766558-30-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-06-9 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-05-8
CMF C24 H40 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-08-1 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-(1-azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N,2,4,6-tetramethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-07-0
CMF C25 H40 N4 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-10-5 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-09-2
CMF C25 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-12-7 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-11-6
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-14-9 CAPLUS
CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-13-8
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-16-1 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-15-0
CMF C25 H42 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-18-3 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-,

2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-17-2
CMF C24 H40 N4 O6 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-20-7 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[2-(1-piperidinyl)ethyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-19-4
CMF C25 H42 N4 O5 S

PAGE 1-A



OMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-22-9 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-21-8
CMF C26 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-24-1 CAPLUS
CN Benzenesulfonamide, N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-23-0

CMF C23 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-26-3 CAPLUS
CN Benzenesulfonamide, 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX

NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-30-9 CAPLUS
CN 1H-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-29-6
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 766558-13-8P, N-[2-[2-[4-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide

RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-13-8 CAPLUS

CN Benzenesulfonamide, N-[2-[2-[4-(3R)-1-azabicyclo[2.2.2]oct-3-yl-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:875251 CAPLUS

DOCUMENT NUMBER: 139:364826

TITLE: Preparation of substituted 3-aminoindolecarboxylates and 3-aminobenzothiophenes as interleukin-4 gene expression inhibitors

INVENTOR(S): Merriman, Gregory H.; Weintraub, Philip M.; Sabol, Jeffrey S.; Dharanipragada, Ramalinga; Hrib, Nicholas J.; Jurcak, John G.; Gross, Alexandre; Whiteley, Brian; Musick, Kwon Yon; Klein, Joseph T.

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091215	A1	20031106	WO 2003-US12661	20030423 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483091	A1	20031106	CA 2003-2483091	20030423 <--
AU 2003225131	A1	20031110	AU 2003-225131	20030423 <--
US 20040006123	A1	20040108	US 2003-421597	20030423 <--
US 20040010029	A1	20040115	US 2003-421511	20030423 <--
US 7169925	B2	20070130		

EP 1501796	A1	20050202	EP 2003-721841	20030423	<--
EP 1501796	B1	20070509			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005529135	T	20050929	JP 2003-587780	20030423	<--
AT 361910	T	20070615	AT 2003-721841	20030423	<--
EP 1834947	A2	20070919	EP 2006-26815	20030423	<--
EP 1834947	A3	20080528			
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR					
US 20080132481	A1	20080605	US 2007-947922	20071130	<--
PRIORITY APPLN. INFO.:			US 2002-375304P	P 20020423	<--
			GB 2002-17920	A 20020802	<--
			EP 2003-721841	A3 20030423	
			US 2003-421597	B1 20030423	
			WO 2003-US12661	W 20030423	

OTHER SOURCE(S): MARPAT 139:364826

IT 618889-08-0P 618889-09-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(target compound; preparation of substituted 3-aminoindolecarboxylates and 3-aminobenzothiophenes as interleukin-4 gene expression inhibitor)

RN 618889-08-0 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-(4-pyridinylamino)-, [methyl(phenylsulfonyl)amino]methyl ester (CA INDEX NAME)



RN 618889-09-1 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-(4-pyridinylamino)-, [methyl[(4-methylphenyl)sulfonyl]amino]methyl ester (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:875250 CAPLUS
DOCUMENT NUMBER: 139:364825
TITLE: Preparation of substituted 3-aminoindolecarboxylates and 3-aminobenzothiophenes as modulators of T helper cells (Th1/Th2)
INVENTOR(S): Alkan, Sefik S.; Dinerstein, Robert J.; Subramaniam,

Arun; Hrib, Nicholas J.; Jurcak, John G.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091214	A1	20031106	WO 2003-US12189	20030423 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483162	A1	20031106	CA 2003-2483162	20030423 <--
AU 2003239150	A1	20031110	AU 2003-239150	20030423 <--
US 20040006123	A1	20040108	US 2003-421597	20030423 <--
US 20040010029	A1	20040115	US 2003-421511	20030423 <--
US 7169925	B2	20070130		
EP 1501797	A1	20050202	EP 2003-733867	20030423 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005529134	T	20050929	JP 2003-587779	20030423 <--
AT 361910	T	20070615	AT 2003-721841	20030423 <--
EP 1834947	A2	20070919	EP 2006-26815	20030423 <--
EP 1834947	A3	20080528		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
US 20080132481	A1	20080605	US 2007-947922	20071130 <--

PRIORITY APPLN. INFO.:			
US 2002-375304P	P	20020423	<--
GB 2002-17920	A	20020802	<--
EP 2003-721841	A3	20030423	
US 2003-421597	B1	20030423	
WO 2003-US12189	W	20030423	

OTHER SOURCE(S): MARPAT 139:364825
IT 618889-08-0P 618889-09-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted 3-aminoindolecarboxylates and 3-aminobenzothiophenes as modulators of T helper cells (Th1/Th2))
RN 618889-08-0 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-(4-pyridinylamino)-, [methyl(phenylsulfonyl)amino]methyl ester (CA INDEX NAME)



RN 618889-09-1 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-(4-pyridinylamino)-, [methyl[(4-methylphenyl)sulfonyl]amino]methyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:460922 CAPLUS
DOCUMENT NUMBER: 139:133710
TITLE: Stereocontrolled Total Synthesis of (-)-Ephedradine A (Orantine)
AUTHOR(S): Kurosawa, Wataru; Kan, Toshiyuki; Fukuyama, Tohru
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo, Tokyo, 113-0033, Japan
SOURCE: Journal of the American Chemical Society (2003), 125(27), 8112-8113
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:133710
IT 566202-92-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereocontrolled total synthesis of (-)-ephedradine A (orantine))
RN 566202-92-4 CAPLUS
CN 3-Benzofurancarboxylic acid, 5-bromo-2,3-dihydro-2-[4-(phenylmethoxy)phenyl]-, 3-[[4-[[(1,1-dimethylethyl)diphenylsilyl]oxy]butyl][(2-nitrophenyl)sulfonyl]amino]propyl ester, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:488719 CAPLUS
DOCUMENT NUMBER: 133:252192
TITLE: Acyloxymethyl as a drug protecting group. Part 7: Tertiary sulfonamidomethyl ester prodrugs of benzylpenicillin: chemical hydrolysis and anti-bacterial activity
AUTHOR(S): Iley, J.; Barroso, H.; Moreira, R.; Lopes, F.; Calheiros, T.
CORPORATE SOURCE: Chemistry Department, The Open University, Milton Keynes, MK7 6AA, UK
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(7), 1629-1636
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:252192
IT 164032-21-7P 164032-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(chemical hydrolysis and anti-bacterial activity of tertiary sulfonamidomethyl ester prodrugs of benzylpenicillin)
RN 164032-21-7 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-, [[(4-chlorophenyl)sulfonyl]methylamino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 164032-22-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,

3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-,
[methyl[(4-nitrophenyl)sulfonyl]amino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 164032-23-9P 295787-99-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chemical hydrolysis and anti-bacterial activity of tertiary sulfonamidomethyl ester prodrugs of benzylpenicillin)
RN 164032-23-9 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-,
[methyl[(4-methylphenyl)sulfonyl]amino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 295787-99-4 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-,
[[(4-bromophenyl)sulfonyl]methylamino]methyl ester, (2S,5R,6R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:244166 CAPLUS
DOCUMENT NUMBER: 133:4639
TITLE: Synthesis of polyaminoalkyl substituted conjugates of pyrrolo[2,1-c][1,4]benzodiazepine involving SNAr

reaction of 2-nitro-5-fluorobenzoate precursors
AUTHOR(S): Matsumoto, Kiyoshi; Iida, Hirokazu; Lown, J. William
CORPORATE SOURCE: Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, 606-8501, Japan
SOURCE: Heterocycles (2000), 52(3), 1015-1020
CODEN: HTCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 271253-05-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of polyaminoalkyl-substituted pyrrolo[2,1-c][1,4]benzodiazepines)
RN 271253-05-5 CAPLUS
CN L-Proline, 1-(5-fluoro-2-nitrobenzoyl)-, 3-[[(4-methylphenyl)sulfonyl][2-[[(4-methylphenyl)sulfonyl][3-(phenylmethoxy)propyl]amino]ethyl]amino]propyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:573386 CAPLUS
DOCUMENT NUMBER: 123:32803
ORIGINAL REFERENCE NO.: 123:6059a,6062a
TITLE: Acyloxymethyl as a drug protecting group. Synthesis and reactivity of N-(acyloxymethyl)sulfonamide prodrugs
AUTHOR(S): Calheiros, Teresa; Iley, Jim; Lopes, Francisca; Moreira, Rui
CORPORATE SOURCE: Faculdade Farmacia, Universidade Lisboa, Lisbon, 1600, Port.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(9), 937-40
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 164032-21-7P 164032-22-8P 164032-23-9P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and kinetics of hydrolysis of (acyloxymethyl)sulfonamide

prodrugs)
RN 164032-21-7 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-,
[[(4-chlorophenyl)sulfonyl]methylamino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 164032-22-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-,
[methyl[(4-nitrophenyl)sulfonyl]amino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 164032-23-9 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-,
[methyl[(4-methylphenyl)sulfonyl]amino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1986:497329 CAPLUS
DOCUMENT NUMBER: 105:97329
ORIGINAL REFERENCE NO.: 105:15728h,15729a
TITLE: Hydroxypropylaminoalkyl pyridinecarboxylates
INVENTOR(S): Triggle, David; Schwenner, Eckhard; Kinast, Guenther; Kazda, Stanislav; Knorr, Andreas; Garthoff, Bernward
PATENT ASSIGNEE(S): Bayer A.-G. , Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 73 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
EP 179386	A2	19860430	EP 1985-113060		19851015	<--
EP 179386	A3	19870805				
EP 179386	B1	19890607				
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE						
NO 8504021	A	19860428	NO 1985-4021		19851010	<--
AT 43838	T	19890615	AT 1985-113060		19851015	<--
FI 8504171	A	19860427	FI 1985-4171		19851024	<--
DK 8504912	A	19860427	DK 1985-4912		19851025	<--
AU 8549097	A	19860501	AU 1985-49097		19851025	<--
JP 61137861	A	19860625	JP 1985-237796		19851025	<--
HU 40080	A2	19861128	HU 1985-4116		19851025	<--
HU 194543	B	19880229				
CN 85107866	A	19860730	CN 1985-107866		19851026	<--
ZA 8508249	A	19860625	ZA 1985-8249		19851028	<--
PRIORITY APPLN. INFO.:			US 1984-664904	A	19841026	<--
			US 1985-769181	A	19850823	<--
			EP 1985-113060	A	19851015	<--

OTHER SOURCE(S): MARPAT 105:97329
IT 103926-46-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiovascular agent)
RN 103926-46-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[3-[[2-hydroxy-3-(1-naphthalenyloxy)propyl][(4-methylphenyl)sulfonyl]amino]propyl] 5-(1-methylethyl) ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	48.73	235.79

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:32:31 ON 20 JAN 2009